Schulz U G, Blamire A M, Corkill R G, Davies P, Styles P, Rothwell P M
Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK.
Brain. 2007 Dec;130(Pt 12):3102-10. doi: 10.1093/brain/awm165. Epub 2007 Oct 22.
Previous studies suggest an abnormal cerebral cortical energy metabolism in migraineurs. If causally related to the pathophysiology of migraine, these abnormalities might show a dose-response relationship with the duration and severity of aura symptoms. While such a trend has been suggested in phosphorus spectroscopy (31P-MRS) studies, it has not been considered in proton spectroscopy (1H-MRS) studies and it has not been studied in cerebral white matter. We aimed to determine whether for any of the metabolites measured by 31P-MRS or 1H-MRS there was a dose-response relationship with aura duration and severity, and whether such an association was also present in cerebral white matter. We studied patients with migraine with aura and healthy controls with 31P-MRS and with 1H-MRS. We measured metabolite ratios in grey and in white matter and in the patients, we related metabolite levels to the clinical characteristics and duration of the aura. In patients, the phosphocreatine/phosphate (PCr/Pi) ratio decreased significantly with increasing aura duration and was significantly lower in patients with hemiplegic migraine than in patients with non-motor aura. Overall the metabolite ratios did not differ significantly between patients and controls, but compared with controls the PCr/Pi ratio in patients with hemiplegic migraine and in patients with persistent aura >7 days was significantly lower. These changes were only present in grey matter. Results for 1H-MRS did not differ significantly between patients and controls, and they showed no association with duration or severity of symptoms. In this study, metabolite ratios differed significantly between patients with different aura phenotypes and with increasing aura duration. In addition, only in some patient subgroups were metabolite ratios significantly different from controls. These findings support the concept that migraine with aura is a heterogeneous disorder with distinct pathophysiological subtypes. They further suggest that rather than determining the susceptibility to developing a migraine attack, changes in cortical energy metabolism may determine the clinical manifestations of the migrainous aura once an attack has started.
以往研究表明偏头痛患者存在大脑皮质能量代谢异常。如果这些异常与偏头痛的病理生理学存在因果关系,那么它们可能与先兆症状的持续时间和严重程度呈现剂量反应关系。虽然磷谱(31P-MRS)研究中已提示存在这种趋势,但质子谱(1H-MRS)研究中尚未考虑,且大脑白质方面也未进行研究。我们旨在确定通过31P-MRS或1H-MRS测量的任何代谢物是否与先兆持续时间和严重程度存在剂量反应关系,以及这种关联在大脑白质中是否也存在。我们对有先兆偏头痛患者和健康对照者进行了31P-MRS和1H-MRS研究。我们测量了灰质和白质中的代谢物比率,在患者中,我们将代谢物水平与先兆的临床特征和持续时间相关联。在患者中,磷酸肌酸/磷酸盐(PCr/Pi)比率随先兆持续时间增加而显著降低,偏瘫性偏头痛患者的该比率显著低于非运动性先兆患者。总体而言,患者与对照者之间的代谢物比率无显著差异,但与对照者相比,偏瘫性偏头痛患者和先兆持续时间>7天的持续性先兆患者的PCr/Pi比率显著更低。这些变化仅存在于灰质中。1H-MRS的结果在患者与对照者之间无显著差异,且未显示出与症状持续时间或严重程度的关联。在本研究中,不同先兆表型的患者以及先兆持续时间增加时,代谢物比率存在显著差异。此外,仅在一些患者亚组中代谢物比率与对照者有显著差异。这些发现支持了有先兆偏头痛是一种具有不同病理生理亚型的异质性疾病这一概念。它们进一步表明,皮质能量代谢的变化可能不是决定发生偏头痛发作的易感性,而是在发作开始后决定偏头痛先兆的临床表现。